RP 4010

Drug Profile

RP 4010

Alternative Names: RP-4010

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rhizen Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action ORAI1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 26 Oct 2017 Interim pharmacokinetic, pharmacodynamic data from preclinical studies in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
  • 11 May 2017 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater, Recurrent) in USA (unspecified route) (NCT03119467)
  • 24 Apr 2017 Rhizen Pharmaceuticals plans a phase I trial for Non-Hodgkin's lymphoma (Second-line therapy or greater, Recurrent) in USA (NCT03119467)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top